Tindamax Treats Both Bacterial Vaginosis (BV) and Trichomoniasis

Bacterial vaginosis frequently occurs in conjunction with trichomoniasis, with significant overlap of BV and TV noted in both clinical findings and bacterial cultures.¹ In published reports, the prevalence of patients with TV who are also positive for BV ranges from 24%-57%.^2-5

Trichomoniasis is the most common non-viral STD in the US, with an estimated 7.4 million new cases annually⁶
Bacterial vaginosis is the most common vaginal infection among women of childbearing years⁷

By reducing normal levels of lactobacilli in the vaginal flora and altering vaginal pH, the presence of Trichomonas vaginalis is believed to create an environment that fosters overgrowth of BV-related microorganisms.⁵

Signs and symptoms of BV and TV present a diagnostic challenge⁸

Multiple challenges exist in the diagnosis of mixed BV and TV infection. Because many patients are asymptomatic, sensitivity of signs and symptoms as a basis for diagnosis of trichomoniasis is low. The most common diagnostic test (wet mount) has a sensitivity of only 60%-70%, which decreases further if samples are not evaluated promptly.⁹

Among patients who are symptomatic, BV and TV infections may have similar signs, including elevated vaginal pH, amine odor, and the presence of homogeneous discharge, which is considered a significant clinical indicator for dual BV/TV diagnosis.⁵

Only Tindamax^® is approved to treat both BV and TV¹⁰

BV and TV share many of the same serious health risks if left untreated, including a higher rate of pelvic inflammatory disease and increased risk for infertility and pre-term birth.^7,9

Tindamax^® offers a single, effective treatment for both BV and TV that is easy to dose and is well tolerated by patients.¹⁰

Tindamax^® combines simple dosing
with systemic effectiveness
2 convenient dosing options for BV		1 simple oral dosing regimen for trichomoniasis (TV)
2 g/2-day dosing 4 x 500 mg tablets once daily for two days, with food	1 g/5-day dosing 2 x 500 mg tablets once daily for five days, with food	2 g/1-day dosing 4 x 500 mg tablets one time, with food





Table 1

Heller DS, Maslyak S, Skurnick J. Is the presence of Trichomonas on a Pap smear associated with an increased incidence of bacterial vaginosis? J Low Genit Tract Dis. 2006 Jul;10(3):137-9.
Krieger JN, Tam MR, Stevens CE, Nielsen IO, Hale J, Kiviat NB, Holmes KK. Diagnosis of trichomoniasis. Comparison of conventional wet-mount examination with cytologic studies, cultures, and monoclonal antibody staining of direct specimens. JAMA. 1988 Feb 26;259(8):1223-7.
Dan M, Sobel JD. Trichomoniasis as seen in a chronic vaginitis clinic. Infect Dis Obstet Gynecol. 1996;4(2):77-84.
Heine RP, McGregor JA, Patterson E, Draper D, French J, Jones W. Trichomonas vaginalis: Diagnosis and Clinical Characteristics in Pregnancy. Infect Dis Obstet Gynecol. 1994;1(5):228-34.
Demirezen S, Korkmaz E, Beksaç MS. Association between trichomoniasis and bacterial vaginosis: examination of 600 cervicovaginal smears. Cent Eur J Public Health. 2005 Jun;13(2):96-8.
Weinstock H, Berman S, Cates W Jr. Sexually transmitted diseases among American youth: incidence and prevalence estimates, 2000. Perspect Sex Reprod Health. 2004 Jan-Feb;36(1):6-10.
Sweet RL. Gynecologic conditions and bacterial vaginosis: implications for the non-pregnant patient. Infect Dis Obstet Gynecol. 2000;8(3-4):184-90.
Sobel JD. Vaginitis. N Engl J Med. 1997 Dec 25;337(26):1896-903.
Nanda N, Michel RG, Kurdgelashvili G, Wendel KA. Trichomoniasis and its treatment. Expert Rev Anti Infect Ther. 2006 Feb;4(1):125-35.
Data on file. Mission Pharmacal Company.